Abstract: This invention provides polymeric nanoparticles presenting non-conjugated BBB-crossing ligands on their surfaces, compositions and methods of use thereof, as well as non-conjugation methods to produce nanoparticles having BBB-crossing agents on their surfaces.

Abstract: This invention provides polymeric nanoparticles presenting non-conjugated BBB-crossing ligands on their surfaces, compositions and methods of use thereof, as well as non-conjugation methods to produce nanoparticles having BBB-crossing agents on their surfaces.

Abstract: This invention provides a pharmaceutical composition comprising an agent that can bind Siglec receptors on cell surface. This invention also provides the method of preparing said pharmaceutical composition and the use thereof.

Abstract: Nanoparticles formed by emulsion of one or more core polymers, one or more surface altering materials, and one or more low molecular weight emulsifiers have been developed. The particles are made by dissolving the one or more core polymers in an organic solvent, adding the solution of the one or more core polymers to an aqueous solution or suspension of the emulsifier to form an emulsion, and then adding the emulsion to a second solution or suspension of the emulsifier to effect formation of the nanoparticles.

Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.

Abstract: The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer. Other aspects include methods of making and using such nanoparticles.

Abstract: Nanoparticles formed by emulsion of one or more core polymers, one or more surface altering materials, and one or more low molecular weight emulsifiers have been developed. The particles are made by dissolving the one or more core polymers in an organic solvent, adding the solution of the one or more core polymers to an aqueous solution or suspension of the emulsifier to form an emulsion, and then adding the emulsion to a second solution or suspension of the emulsifier to effect formation of the nanoparticles. In the preferred embodiment, the molecular weight of the emulsifiers is less than 1500, 1300, 1200, 1000, 800, 600, or 500 amu. Preferred emulsifiers include cholic acid sodium salt, dioctyl sulfosuccinate sodium, hexadecyltrimethyl ammonium bromide, saponin, TWEEN® 20, TWEEN® 80, and sugar esters. The surface altering materials are present in an amount effective to make the surface charge of the particles neutral or essentially neutral when the one or more emulsifiers are charged.